PPARγ activation has been shown to ameliorate the severity of inflammatory bowel disease in rodent DSS, trinitrobenzene sulphonic acid, and ischemic colitis models [20], [27], [30], [32], [33]. This evidence concerns the gene PPARG and inflammatory bowel disease.